Trials indicate that screening women between 40 and 49 with mammography results in a clear mortality benefit. Whether this is worth the side-effects and financial cost is a matter of judgement. Some national health authorities and several other bodies consider the balance favourable enough to recommend general screening for this age group.
No takes yet. Share an insight, caveat, or question.
Ingvar Andersson (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: